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Introduction
Colorectal cancer (CRC) is a major cause of cancerrelated death in the USA [1] , with approximately 150,000 new diagnoses and 50,000 deaths from CRC projected in 2019 alone [2] . With widespread screening initiatives to detect CRC and pre-cancerous polyps, CRCrelated morbidity and mortality have decreased in recent years [2] . The US Preventive Services Task Force (USPSTF) recommends screening for CRC in averagerisk adults between the ages of 50 and 75 [3] , while more recent recommendations from the American Cancer Society (ACS) suggest initiating screening at age 45 in light of the increasing rate of CRC diagnosed in younger patients [4•,5,6,7,8] . However, despite these guidelines and extensive public health initiatives, approximately one-third of screen-eligible adults in the USA remain unscreened [9, 10•] .
Several methods are recommended for CRC screening [3, 4•, 11•] . Colonoscopy is the most widely used modality in the USA [9] and permits simultaneous diagnostic and therapeutic intervention for colorectal neoplasia (CRN). However, screening colonoscopy has several notable drawbacks, including reduced sensitivity in the proximal colon [12-18•] and inter-operator variability in colonoscopy quality [19] [20] [21] [22] . Furthermore, its invasive nature; risk of complications; and the inconvenience of preparation, sedation, and time away from work are recognized barriers to patients considering screening [23] . Several non-invasive screening modalities are endorsed as an alternative to colonoscopy for use in average-risk patients. Guaiac-based fecal occult blood testing (gFOBT) has the strongest body of evidence demonstrating a reduction in CRC-related mortality [24] [25] [26] [27] . However, dietary and medication interactions, poor performance in the proximal colon, and issues with adherence to the recommended yearly screening interval have led to decreased utilization of this test [28] [29] [30] . The introduction of fecal immunochemical testing (FIT) addressed some of these limitations, with FIT included as a first-line option in major society screening guidelines [3, 11•] . A recent meta-analysis suggested moderate-to-high sensitivity and specificity for CRC and advanced adenoma (AA) in a singleuse setting, but performance varied by assay and positivity cutoff [31] . Concerns remain regarding reduced sensitivity for right-sided and sessile serrated precursor lesions [28, 29, 32 •] in addition to persistent poor adherence to required annual testing [30, [33] [34] [35] [36] .
Multi-target stool DNA testing
Multi-target stool DNA (MT-sDNA) is a newer stool-based screening modality, with one commercial product available to patients in the USA (Cologuard™, Exact Sciences, Madison, WI). This test detects abnormal DNA markers (aberrantly methylated BMP3 and NDRG4, mutant KRAS) shed from neoplastic cells in the gastrointestinal tract. Another marker, β-actin, serves as a control to ensure adequate quantity of DNA in the sample, while an immunochemical assay for hemoglobin detects evidence of gastrointestinal bleeding. These components are measured quantitatively and incorporated into a logistic regression algorithm containing mathematical interaction variables for each marker. These interaction terms result in numerous marker combinations that can trigger a pre-specified threshold score, resulting in a positive or negative test result that is more than the sum of its individual components [37] .
MT-sDNA testing is performed by the patients in the comfort of their own home. Following a provider order, a manufacturer-based patient navigation office contacts the patient and arranges sample collection via a courier-delivered kit [38] . This system also provides patient education and test completion reminders which have been shown to result in adherence to testing of over 70% in Medicare beneficiaries [38] . Following delivery of the MT-sDNA kit, patients collect a whole stool sample, swab a portion to collect the FIT sample, add a preservative buffer to the whole stool, seal the container, and mail the samples in one box back to the laboratory for analysis.
MT-sDNA testing was approved for screening in average-risk adults by the US Food and Drug Administration (FDA) in 2014, following a large screen-setting trial by Imperiale et al. (DeeP-C trial), comparing MT-sDNA and FIT. Overall, the sensitivity of MT-sDNA for detecting CRC in this study was 92% (vs 74% for FIT, p = 0.002), and 42% for advanced precancerous lesions (vs 24% for FIT, p G 0.001) [39] . A second study performed in an Alaska Native cohort confirmed these findings, and redemonstrated increasing sensitivity by adenoma size, with 80% sensitivity for lesions 9 3 cm, and 100% sensitivity for CRC [40••] . Specificity was 87-94% across these two studies, and increased in younger patients (Table 1 ) [39, 40••] . MT-sDNA appears to have similar performance for the detection of both conventional adenomas and sessile serrated polyps (SSPs). Large SSPs and hyperplastic polyps (≥ 1 cm) were included in the sensitivity estimate for advanced pre-cancerous lesions in the DeeP-C study [39] . For greater clarity, a post hoc analysis of DeeP-C data was performed on all lesions ≥ 1 cm with histology confirmed for SSP. The median size was 1.2 cm (range 1-3), and the majority (28/29 (93%)) were located proximal to the splenic flexure; only one SSP contained dysplasia. In this setting, MT-sDNA had a sensitivity of 55% (95% CI, 36-74%) and a specificity of 91% [41] . MT-sDNA performance characteristics for the individual endpoint category of large hyperplastic polyp have not been estimated and traditional serrated adenomas were not identified by screening colonoscopy in the DeeP-C study; these endpoints are deserving of future study.
Population modeling studies performed as part of a USPSTF review suggest that programmatic use of MT-sDNA would result in fewer lifetime colonoscopies than FIT and a stronger benefit-to-harms ratio than colonoscopy (Table 2 ) [3] . As a result of the above findings, MT-sDNA testing was subsequently endorsed by the USPSTF in their 2016 guidelines for CRC screening [3] . Utilization of MT-sDNA has been increasing exponentially since then, with nearly 3 million screens performed to date [42] . [44] . While there may be many reasons for patients to go without screening, these findings suggest that MT-sDNA is attracting previously nonadherent patients, a critical outcome in the ongoing long-term fight to reduce CRC-attributable mortality. Of all patients screened with MT-sDNA, 14-16% will have positive results [39, 44, 45] . Following a positive MT-sDNA test, it is imperative that patients undergo diagnostic colonoscopy to evaluate for CRN. While previous estimates of adherence to diagnostic colonoscopy ranged from 75 to 96% [43•, 45] , our recent analysis showed a diagnostic colonoscopy completion rate of~90% in a large multi-practice setting [44] . Reasons for non-adherence to recommended diagnostic colonoscopy vary, but are commonly related to a wish to avoid colonoscopy, in addition to medical comorbidities that preclude sedation and procedural intervention [45] . These factors illustrate the importance of both provider and patient education prior to pursuing MT-sDNA testing in order to ensure selection of appropriate patients for screening with this test.
In patients with positive MT-sDNA testing who undergo diagnostic colonoscopy, our data show that approximately two-thirds will be found to have at least one neoplastic lesion [44] . Among patients with CRN, 40% will have at least one advanced lesion (defined as CRC, adenomas, or SSPs with at least one of the following characteristics: ≥ 1 cm in size, high-grade dysplasia, or having ≥ 25% villous elements), and~1% will have CRC. SSPs will be detected in about half of patients with positive tests. Importantly, MT-sDNA testing appears to perform well in detecting rightsided (proximal) neoplasia. In our multi-site cohort of patients with positive MT-sDNA tests, over 50% of patients overall (and 80% of those with neoplastic lesions) were found to have proximal CRN [44] . The reason for the high yield of proximal CRC is likely multifactorial, although improved detection resulting from the multiple markers in MT-sDNA offers one potential explanation. Rightsided lesions tend to be flat and less likely to bleed [46] , and exfoliation of DNA markers is more consistent throughout the colon [47] ; therefore, MT-sDNA has an advantage over other non-invasive methods for the detection of right-sided neoplasia.
These point estimates for positive predictive value appear higher than reported in the pre-FDA approval trial, where advanced lesions were found in 24% of those with positive MT-sDNA tests [39] . This is likely in part due to underlying differences in the populations being studied, or in differences in those opting to use the test in clinical practice versus the clinical trial setting. However, there are several other factors that likely contribute to the high yield of MT-sDNA for CRN, both proximal and distal. First, by screening an average-risk population with MT-sDNA and performing further testing only in those with positive results, this creates an enriched population in whom the pre-test probability of CRN at diagnostic colonoscopy is increased. Furthermore, studies have shown that endoscopist knowledge of a positive MT-sDNA test significantly increases quality metrics such as ADR at diagnostic colonoscopy compared with blinded endoscopists, likely related to longer withdrawal time and increased attention to subtle lesions ( Fig. 1) [48••] . Moreover, recent data suggest that while improvement in quality and yield of diagnostic colonoscopy is observed in all endoscopists in a large academic practice, the greatest improvement in polyp detection is seen in gastroenterologists with lower baseline detection rates [49].
"False positive" MT-sDNA tests
A common question among physicians and other health care providers is what should be done in the setting of a positive MT-sDNA test followed by a negative colonoscopy (a "false positive" MT-sDNA test). However, before addressing this question, negative colonoscopy needs to be more clearly defined. The original studies investigating MT-sDNA testing labeled true positive tests as those in which only advanced neoplasia or CRC was detected [39] . However, we have shown that approximately 40% of lesions detected by MT-sDNA are nonadvanced [44] ; a positive MT-sDNA test in these situations is therefore unlikely to be biologically false, but rather to have detected exfoliated DNA from a neoplasm not meeting arbitrary size-based criteria. With this in mind, knowing that 14% of all MT-sDNA tests are positive and that 67% of these patients have CRN found at diagnostic colonoscopy, less than 5% of all patients screened with MT-sDNA would have no polyps found at colonoscopy (14.1% × (100% − 67%) = 4.7%). Even when including only advanced CRN and CRC, 10% (14.1% × (100% − 28%)) would have false positive results.
In the clinical situation of a false positive MT-sDNA test, the next step is to ensure that a diagnostic colonoscopy of sufficient quality was performed. In clinical trials of MT-sDNA, only those with high-quality colonoscopy, defined as having good or excellent bowel preparation, photographic evidence of cecal intubation, and withdrawal time of ≥ 6 min, were included in primary study outcomes [21, 39, 40••, 50] . Assuming a high-quality colonoscopy, current guidelines suggest that no further testing be performed [11•] . These recommendations are based on several studies that found no increased risk of CRC in this specific population. One such study prospectively evaluated 30 patients with initial false positive MT-sDNA testing (evaluated by both colonoscopy and esophagogastroduodenoscopy (EGD)), who underwent repeat MT-sDNA and colonoscopy/EGD 1 year later. In this cohort, only two advanced lesions were found on repeat testing; however, information on initial colonoscopy quality was not reported [51•] . Another study 
Future directions
Even with increasing utilization of MT-sDNA and the emergence of postapproval performance data, several opportunities for further study remain. While the current recommended testing interval for MT-sDNA is 3 years, this is based on manufacturer's recommendations and computer modeling, and further investigation is needed into MT-sDNA performance with different testing frequencies.
Additional study of patient adherence to both the testing schedule and diagnostic colonoscopy in other populations would also help to further inform test performance in the real world. MT-sDNA testing may benefit additional patient populations. In response to the ACS recommendation to begin screening for CRC at age 45, studies conducted in archival tissue specimens demonstrated that MT-sDNA markers in primary CRC tumors among those 45-49 years old at diagnosis are similar to those seen in tumors of patients aged 50-64 [54] ; methylated DNA markers were all substantially higher than observed in control tissues across these age ranges. As a result of these data and those expected from a clinical trial utilizing MT-sDNA in patients age 45-49 (ClinicalTrials.gov Identifier: NCT03728348), the FDA recently expanded the label for MT-sDNA to include those age 45-84.
The FDA's current labeling excludes those at increased risk for CRC due to conditions such as inflammatory bowel disease (IBD), personal history of advanced CRN, family history of early CRC, and signs of blood loss, among others. Initial data from our group's evaluation of off-label use of MT-sDNA testing (~10% of tests) in patients with these risk factors show that test performance is similar to those at average risk [55] . Furthermore, in a research study of 192 patients with IBD undergoing MT-sDNA testing for surveillance, the test demonstrated similar sensitivity for both CRC and CRN when compared with the general population [56• ]. However, further study is needed before extending MT-sDNA use into these increased-risk populations.
Finally, MT-sDNA may have important utility as an interval test following apparently negative colonoscopy. In our group's analysis of data in patients undergoing MT-sDNA testing within 5 years of a negative colonoscopy, the yield of all CRN and most CRN subtypes was the same as in those undergoing testing 10 or more years after colonoscopy. When these patients were further stratified by whether their prior colonoscopy was complete or incomplete (e.g., poor prep, no cecal intubation), neoplastic yield remained similar between groups [57] . Advanced neoplasms were found in 16-17% of those screened early with MT-sDNA; these findings could not be explained by known elevations in baseline risk. Taken together, these findings suggest that lesions are likely being missed at screening colonoscopies. MT-sDNA should therefore be studied as a tool between colonoscopies to identify those in which polyps were likely to have been missed, and thereby reduce the risk of interval CRC.
Conclusion
MT-sDNA is a stool-based screening test with high sensitivity and specificity for both CRN and CRC. As its use has increased over the past 5 years after FDA approval, it has attracted a large population of previously non-adherent patients to screening. A majority of patients with a positive test are found to have CRN at diagnostic colonoscopy, with most harboring right-sided lesions. While further investigation is necessary into additional potential uses, MT-sDNA has firmly cemented itself as a convenient, non-invasive, and effective tool for widespread screening in the ongoing fight against CRC.
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